This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hammerschlag, M R
Right arrow Articles by Roblin, P M
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hammerschlag, M R
Right arrow Articles by Roblin, P M

 Previous Article  |  Next Article 

Antimicrob Agents Chemother. 1992 July; 36(7): 1573-1574

In vitro activities of azithromycin, clarithromycin, L-ofloxacin, and other antibiotics against Chlamydia pneumoniae.

M R Hammerschlag, K K Qumei and P M Roblin

Department of Pediatrics and Medicine, State University of New York, Brooklyn 11203.

ABSTRACT

The in vitro susceptibilities of 11 strains of Chlamydia pneumoniae to azithromycin, clarithromycin, erythromycin, L-oflaxacin, and doxycycline were determined. Clarithromycin was the most active agent tested, with an MIC for 90% of strains and minimal chlamydiacidal concentration for 90% of strains of 0.03 microns/ml. The activity of azithromycin was similar to those of erythromycin and doxycycline, with MICs for 90% of strains of 0.125 to 0.25 microns/ml. However, the prolonged half-life and enhanced tissue penetration of azithromycin should allow for less frequent dosing and shorter duration of therapy than with erythromycin or clarithromycin. L-Ofloxacin had activity similar to that of ofloxacin, with MICs of 0.125 to 0.5 micron/ml. From the results of this in vitro study, azithromycin and clarithromycin appear to be effective antibiotics that may have a role in the treatment of infections due to C. pneumoniae.

Antimicrob Agents Chemother. 1992 July; 36(7): 1573-1574




This article has been cited by other articles:

  • Goy, G., Greub, G. (2009). Antibiotic Susceptibility of Waddlia chondrophila in Acanthamoeba castellanii Amoebae. Antimicrob. Agents Chemother. 53: 2663-2666 [Abstract] [Full Text]  
  • Foleno, B. D., Abbanat, D., Goldschmidt, R. M., Flamm, R. K., Paget, S. D., Webb, G. C., Wira, E., Macielag, M. J., Bush, K. (2007). In Vitro Antibacterial Activity of the Pyrrolopyrazolyl-Substituted Oxazolidinone RWJ-416457. Antimicrob. Agents Chemother. 51: 361-365 [Abstract] [Full Text]  
  • Gotfried, M. H. (2004). Macrolides for the Treatment of Chronic Sinusitis, Asthma, and COPD. Chest 125 : 52S-61S [Abstract] [Full Text]  
  • Roblin, P. M., Reznik, T., Kutlin, A., Hammerschlag, M. R. (2003). In Vitro Activities of Rifamycin Derivatives ABI-1648 (Rifalazil, KRM-1648), ABI-1657, and ABI-1131 against Chlamydia trachomatis and Recent Clinical Isolates of Chlamydia pneumoniae. Antimicrob. Agents Chemother. 47: 1135-1136 [Abstract] [Full Text]  
  • Erkens, J.A., Klungel, O.H., Herings, R.M.C., Stolk, R.P., Spoelstra, J.A., Grobbee, D.E., Leufkens, H.G.M. (2002). Use of fluorquinolones is associated with a reduced risk of coronary heart disease in diabetes mellitus type 2 patients. Eur Heart J 23: 1575-1579 [Abstract] [Full Text]  
  • Fong, I. W., Chiu, B., Viira, E., Jang, D., Mahony, J. B. (2002). Influence of Clarithromycin on Early Atherosclerotic Lesions after Chlamydia pneumoniae Infection in a Rabbit Model. Antimicrob. Agents Chemother. 46: 2321-2326 [Abstract] [Full Text]  
  • Kutlin, A., Roblin, P. M., Hammerschlag, M. R. (2002). Effect of Prolonged Treatment with Azithromycin, Clarithromycin, or Levofloxacin on Chlamydia pneumoniae in a Continuous-Infection Model. Antimicrob. Agents Chemother. 46: 409-412 [Abstract] [Full Text]  
  • Guthrie, R. (2001). Community-Acquired Lower Respiratory Tract Infections : Etiology and Treatment. Chest 120: 2021-2034 [Abstract] [Full Text]  
  • Strigl, S., Roblin, P. M., Reznik, T., Hammerschlag, M. R. (2000). In Vitro Activity of ABT 773, a New Ketolide Antibiotic, against Chlamydia pneumoniae. Antimicrob. Agents Chemother. 44: 1112-1113 [Abstract] [Full Text]  
  • Moss, P. J, Finch, R. G (2000). The next generation: fluoroquinolones in the management of acute lower respiratory infection in adults. Thorax 55: 83-85 [Full Text]  
  • Fong, I. W., Chiu, B., Viira, E., Jang, D., Fong, M. W., Peeling, R., Mahony, J. B. (1999). Can an Antibiotic (Macrolide) Prevent Chlamydia pneumoniae-Induced Atherosclerosis in a Rabbit Model?. CVI 6: 891-894 [Abstract] [Full Text]  
  • Roblin, P. M., Reznik, T., Kutlin, A., Hammerschlag, M. R. (1999). In Vitro Activities of Gemifloxacin (SB 265805, LB20304) against Recent Clinical Isolates of Chlamydia pneumoniae. Antimicrob. Agents Chemother. 43: 2806-2807 [Abstract] [Full Text]  
  • Kutlin, A., Roblin, P. M., Hammerschlag, M. R. (1999). In Vitro Activities of Azithromycin and Ofloxacin against Chlamydia pneumoniae in a Continuous-Infection Model. Antimicrob. Agents Chemother. 43: 2268-2272 [Abstract] [Full Text]  
  • Fish, D. N., Abraham, E. (1999). Pharmacokinetics of a Clarithromycin Suspension Administered via Nasogastric Tube to Seriously Ill Patients. Antimicrob. Agents Chemother. 43: 1277-1280 [Abstract] [Full Text]  
  • Torgano, G., Cosentini, R., Mandelli, C., Perondi, R., Blasi, F., Bertinieri, G., Van Tien, T., Ceriani, G., Tarsia, P., Arosio, C., Ranzi, M. L. (1999). Treatment of Helicobacter pylori and Chlamydia pneumoniae Infections Decreases Fibrinogen Plasma Level in Patients With Ischemic Heart Disease. Circulation 99: 1555-1559 [Abstract] [Full Text]  
  • Meier, C. R., Derby, L. E., Jick, S. S., Vasilakis, C., Jick, H. (1999). Antibiotics and Risk of Subsequent First-time Acute Myocardial Infarction. JAMA 281: 427-431 [Abstract] [Full Text]  
  • Roblin, P. M., Hammerschlag, M. R. (1998). In Vitro Activity of a New Ketolide Antibiotic, HMR 3647, against Chlamydia pneumoniae. Antimicrob. Agents Chemother. 42: 1515-1516 [Abstract] [Full Text]  
  • Chien, S.-C., Wong, F. A., Fowler, C. L., Callery-D'Amico, S. V., Williams, R. R., Nayak, R., Chow, A. T. (1998). Double-Blind Evaluation of the Safety and Pharmacokinetics of Multiple Oral Once-Daily 750-Milligram and 1-Gram Doses of Levofloxacin in Healthy Volunteers. Antimicrob. Agents Chemother. 42: 885-888 [Abstract] [Full Text]  
  • Roblin, P. M., Hammerschlag, M. R. (1998). In Vitro Activity of a New 8-Methoxyquinolone, BAY 12-8039, against Chlamydia pneumoniae. Antimicrob. Agents Chemother. 42: 951-952 [Abstract] [Full Text]  
  • Roblin, P. M., Hammerschlag, M. R. (1998). Microbiologic Efficacy of Azithromycin and Susceptibilities to Azithromycin of Isolates of Chlamydia pneumoniae from Adults and Children with Community-Acquired Pneumonia. Antimicrob. Agents Chemother. 42: 194-196 [Abstract] [Full Text]  
  • Thom, D. (1994). Lower Respiratory Tract Infection With Chlamydia pneumoniae. Arch Fam Med 3: 828-832 [Abstract]  
  • Emre, U., Roblin, P. M., Gelling, M., Dumornay, W., Rao, M., Hammerschlag, M. R., Schachter, J. (1994). The Association of Chlamydia pneumoniae Infection and Reactive Airway Disease in Children. Arch Pediatr Adolesc Med 148: 727-732 [Abstract]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»